Gamida Cell Ltd.
BiotechGamida Cell Ltd. is a biotechnology company focused on Oncology.
Gamida Cell Ltd. at a Glance
- Strong track record with 85% execution quality across 7 trials
Gamida Cell Ltd.'s Key Drugs
Gamida Cell Ltd.'s core commercial portfolio centers on OMISIRGE, spanning Oncology — its most strategically important drugs approved in the last 15 years.
Gamida Cell Ltd.'s Recent FDA Approvals
New NDA/BLA approvals for Gamida Cell Ltd. over the last two years — novel drugs only, excluding generics and label supplements.
Gamida Cell Ltd.'s Therapeutic Areas
Gamida Cell Ltd.'s approved drugs and pipeline span 1 therapeutic area, led by Oncology. Weighted by commercial stage — approved drugs count most, then late-stage trials.
Gamida Cell Ltd.'s Top Competitors
Gamida Cell Ltd.'s closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
Gamida Cell Ltd. Pipeline Snapshot
Gamida Cell Ltd. has 4 active clinical programs from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 3 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • OMISIRGE leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 2/2 completed
- • Speed: 59 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 2023-04-16
- Latest
- 2023-04-16
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges